Analytical Data
-
Gene name
CLDN9
- Application
-
Alternative Names
CLDN9；Claudin-9
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95484
-
Expression Region
1-217aa
-
AA Sequence
MASTGLELLGMTLAVLGWLGTLVSCALPLWKVTAFIGNSIVVAQVVWEGLWMSCVVQSTGQMQCKVYDSLLALPQDLQAARALCVIALLLALLGLLVAITGAQCTTCVEDEGAKARIVLTAGVILLLAGILVLIPVCWTAHAIIQDFYNPLVAEALKRELGASLYLGWAAAALLMLGGGLLCCTCPPPQVERPRGPRLGYSIPSRSGASGLDKRDYV
-
Molecular Weight
24.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Claudin-9 (CLDN9) is a member of the claudin family of proteins, which are essential components of tight junctions found in epithelial and endothelial cells. These tight junctions regulate paracellular permeability and are crucial for maintaining tissue homeostasis and barrier integrity. Recent research has highlighted the role of CLDN9 in various physiological and pathological processes, including renal function, inflammation, and cancer. Notably, CLDN9 expression has been linked to tumor progression and metastasis in certain cancers, making it a potential biomarker and therapeutic target. The recombinant expression of CLDN9 allows for the detailed study of its structure-function relationships and interactions with other tight junction proteins, as well as its role in cellular signaling pathways. By generating recombinant CLDN9 proteins, researchers aim to elucidate the mechanisms underlying tight junction formation and maintenance, as well as the protein's involvement in disease states. This research holds promise for developing novel therapeutic strategies aimed at modulating tight junctions to treat diseases associated with altered permeability, inflammation, and cancer progression.
